LP
LENZ

LMR Partners’s LENZ Therapeutics LENZ Stock Holding History

LMR Partners’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,504
Closed -$33K – 1298
2022
Q3 		$33K Hold
1,504
– – ﹤0.01% 1132
2022
Q2 		$29K Buy
+1,504
New +$33.5K ﹤0.01% 1210
2021
Q3 		– Sell
-10,000
Closed -$2.15M – 1229
2021
Q2 		$2.15M Buy
+10,000
New +$1.74M 0.03% 347

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

LMR Partners's LENZ Position: Q4 2022 in Review

LMR Partners sold out of LENZ Therapeutics (LENZ) in Q4 2022, closing a stake of 1,504 shares — an estimated $33K sold.

LMR Partners first reported a position in LENZ in Q2 2021 and held it in 3 quarters. The position peaked at $2.15M in Q2 2021. 66 funds tracked by Wall St. Rank hold LENZ as of Q4 2022.

  • LMR Partners reported no remaining LENZ Therapeutics position as of Q4 2022 after selling out during the quarter.
  • LMR Partners sold 1,504 LENZ Therapeutics shares in Q4 2022, an estimated $33K.
  • LMR Partners first reported a position in LENZ Therapeutics in Q2 2021 and held it in 3 quarters.
  • LMR Partners's LENZ Therapeutics position peaked at $2.15M in Q2 2021.
  • 66 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.